Travere Therapeutics, Inc.
TVTXNasdaqCIK 1438533HealthcareFiscal year ends Dec 31
Reports and events: 332 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2120:10 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001438533-26-000068 |
| 2026-08-0420:45 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001438533-26-000063 |
| 2026-08-0420:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-26-000062 |
| 2026-07-0921:10 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001438533-26-000054 |
| 2026-06-1620:34 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001438533-26-000048 |
| 2026-06-0211:05 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-252474 |
| 2026-05-2120:07 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001438533-26-000046 |
| 2026-05-1121:10 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-217100 |
| 2026-05-0420:45 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001438533-26-000042 |
| 2026-05-0420:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-26-000041 |
| 2026-04-1400:44 ET | 8-K | 8.01 Other events | 0001438533-26-000032 |
| 2026-04-0620:07 ET | DEF 14A | Proxy statementPeriod 2026-05-19 | 0001438533-26-000027 |
| 2026-02-1921:47 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001438533-26-000014 |
| 2026-02-1921:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-26-000013 |
| 2026-01-1321:32 ET | 8-K | 8.01 Other events | 0001438533-26-000005 |
| 2026-01-1222:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-26-000003 |
| 2025-10-3020:46 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001438533-25-000056 |
| 2025-10-3020:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-25-000055 |
| 2025-09-1011:05 ET | 8-K | 8.01 Other events | 0001438533-25-000049 |
| 2025-08-0621:16 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001438533-25-000046 |
| 2025-08-0620:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-25-000045 |
| 2025-05-1620:13 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001438533-25-000034 |
| 2025-05-1520:29 ET | 8-K | 8.01 Other events | 0001438533-25-000032 |
| 2025-05-0121:21 ET | 8-K/A | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-25-000030 |
| 2025-05-0120:47 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001438533-25-000026 |
| 2025-05-0120:05 ET | 8-K | 2.01 Completion of an acquisition or disposition; 9.01 Financial statements and exhibits | 0001438533-25-000025 |
| 2025-04-3021:54 ET | 8-K | 8.01 Other events | 0001438533-25-000020 |
| 2025-04-0120:06 ET | DEF 14A | Proxy statementPeriod 2025-05-15 | 0001438533-25-000016 |
| 2025-03-1720:57 ET | 8-K | 8.01 Other events | 0001438533-25-000012 |
| 2025-02-2101:36 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001438533-25-000010 |
| 2025-02-2021:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-25-000008 |
| 2025-02-1112:05 ET | 8-K | 8.01 Other events | 0001438533-25-000004 |
| 2025-01-1312:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-25-000002 |
| 2024-11-0821:13 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-254153 |
| 2024-10-3112:36 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001438533-24-000048 |
| 2024-10-3112:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-24-000046 |
| 2024-09-2620:02 ET | 8-K | 8.01 Other events | 0001438533-24-000038 |
| 2024-09-0621:47 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001438533-24-000035 |
| 2024-08-0120:40 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001438533-24-000031 |
| 2024-08-0120:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-24-000030 |
| 2024-05-1320:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001438533-24-000022 |
| 2024-05-0620:46 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001438533-24-000020 |
| 2024-05-0620:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-24-000019 |
| 2024-04-2420:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001438533-24-000016 |
| 2024-03-2720:31 ET | DEF 14A | Proxy statementPeriod 2024-05-08 | 0001438533-24-000012 |
| 2024-02-2321:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001438533-24-000007 |
| 2024-02-2013:10 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001438533-24-000005 |
| 2024-02-1521:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001438533-24-000003 |
| 2024-01-0812:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-003866 |
| 2023-12-0421:10 ET | 8-K | 2.05 Exit or disposal costs; 8.01 Other events; 9.01 Financial statements and exhibits | 0001438533-23-000050 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.